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Background: Persistent fever after intravenous immunoglobulin (IVIG) is considered to be a major criterion of IVIG
resistance in Kawasaki disease (KD), and a risk factor for the development of coronary artery abnormalities (CAA).
However, the importance of persistent non-fever symptoms after defervescence has not yet been investigated. We
examined the relationship between persistent non-fever symptoms and CAA in KD.
Methods: We conducted a retrospective cohort study of patients hospitalized with KD at the National Center for
Child Health and Development between 1 April 2008 and 31 March 2009. Patients were divided into two groups;
group A included patients who still had non-fever symptoms one month after onset of the illness and group B
included patients who did not have persistent non-fever symptoms. Demographic, clinical variables were compared
between the groups.
Results: Seventy-seven KD patients treated with IVIG were retrospectively analyzed. Patients were divided into two
groups; group A included 12 (15.6%) patients and group B 65 (84.4%) patients. Demographic data, baseline
laboratory data, and fever duration did not differ between the groups. In group A patients the most common
persistent non-fever symptoms were lip erythema (n = 6) and bulbar conjunctivitis (n = 8). One month after onset of
the illness CAA developed in seven of 77 patients (9.1%), four (33%) in group A and three (4.6%) in group B
(odds ratio 10.3; 95% CI 1.9-54.8). Three patients in group A and one patient in group B developed CAA after the
resolution of fever.
Conclusions: Persistence of non-fever symptoms after IVIG may suggest persistence of latent inflammation, which
may increase the risk of CAA. Therefore, patients with persistent non-fever symptoms may be at risk of developing
CAA, even after defervescence. A prospective trial of additional IVIG for such patients should be considered.
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Kawasaki disease (KD) was first described by Dr. Tomisaku
Kawasaki in 1967 [1]. While the etiology remains un-
known, the annual incidence of KD in Japan increased by
17% during 2005–2008 and currently nearly 12,000 new
cases are reported each year [2]. High-dose intravenous
immunoglobulin (IVIG) is administered as a standard* Correspondence: fukuda-s@ncchd.go.jp
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reproduction in any medium, provided the orinitial treatment [3-5], but 10–20% of patients do not re-
spond to IVIG. Because the effectiveness of the treatment
of KD has been defined by the resolution of fever [6], IVIG
resistance have focused more on the persistence of fever
than on other KD symptoms [7-9]. Little is known about
the impact of the persistence of non-fever symptoms on
the development of coronary artery abnormalities (CAA).
However, we have frequently observed patients whose
non-fever KD symptoms remained after fever subsided.
Most of them were not been received additional treat-
ments, and some developed CAA during the subacute
phase. The objective of our study was to determine theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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KD and CAA.
Methods
We conducted a retrospective cohort study of patients
hospitalized with KD at the National Center for Child
Health and Development between 1 April 2008 and 31
March 2009. The diagnosis of KD was based on the
Diagnostic Guidelines for Kawasaki Disease [10]. We ex-
cluded patients whose symptoms resolved without IVIG.
The remaining patients were evaluated one month after
the onset of illness and were followed up for more than
one year.
The following variables were obtained for each subject
from the electronic medical records: sex, age, the numbers
of major symptoms of KD, fever duration, and duration of
hospitalization. Laboratory data collected prior to initial
treatment included white blood cell count, absolute neu-
trophil count, hematocrit, platelet count, erythrocyte sedi-
mentation rate, albumin, sodium, C-reactive protein (CRP),
total bilirubin, aspartate aminotransferase, alanine amino-
transferase, fibrinogen, and D-dimer.
The initial treatment for KD consists of aspirin 50 mg/
kg/day, and IVIG 2 g/kg. For patients with persistent
fever, additional treatments, including a second adminis-
tration of IVIG, infliximab, and plasma exchange were
considered.
Patients were classified into two groups based on the
presence (group A) or absence (group B) of persistent
non-fever symptoms at one month after the onset of ill-
ness. Fever was defined as axillary temperature >38°C mea-
sured using a digital thermometer. Presence of non-fever
symptoms was defined the routine follow-up visit after
hospital discharge: bilateral conjunctivitis, polymorphousTable 1 Demographic and clinical variables
Group A (n =
Median (Min–
Sex (Male/Female) M 7/F 5
Age (months) 27 (4–65)
Presenting symptoms (in KD criteria) 5 (5–6)
Fever duration (days) 7 (4–10)
Duration of hospitalization (days) 11 (7–38)
CA involvement (n) 4
Treatment
Aspirin/Flurbiprofen (day of administration)† 4 (3–8)
Initial IVIG (day of administration)† 4 (4–8)
Second IVIG (n) 6
Alternative Treatments 3rd IVIG
Total IVIG dosage (g/kg) 3 (2–6)
Note: *Mann-Whitney test **chi-square test, odds ratio 10.3 (95% CI 1.9–54.8).
†Day calculated by subtrating date fever began from date treatment began.
PE Plasma Exchange, N.S. Not significant.exanthema, strawberry tongue or lip erythema, non-
purulent cervical lymphadenopathy, and changes in the ex-
tremities. All subjects were examined in an outpatient
clinic one month after the onset of illness and CAA were
diagnosed using ultrasound based on the Japanese Ministry
of Health, Labor and Welfare criteria [11].
Mann-Whitney test was used to determine the signifi-
cance of demographic and clinical variables between the
two groups. Differences were considered significant at
the p < 0.05 level. The risk of developing CAA was deter-
mined using the chi-square test. All analyses were car-
ried out using SPSS Statistics 17.0 (SPSS Japan, Tokyo).
Approval of the study protocol was obtained from the
Review Board of the National Center for Child Health
and Development and written informed consent was
obtained from the parents of the patients.
Results
During the study period, 81 patients were diagnosed
with KD. After excluding four patients whose symptoms
resolved without IVIG, 77 patients were analyzed. Based
on the persistence of non-fever symptoms, 12 patients
(15.6%) were assigned to group A, and 65 patients (84.4%)
were assigned to group B.
Persistent non-fever symptoms in group A patients in-
cluded lip erythema (4/12), bulbar conjunctivitis (7/12),
and both lip erythema and bulbar conjunctivitis (1/12).
The groups did not differ based on sex, age, hospitalization
date, the number of KD symptoms before the initial IVIG,
fever duration, or duration of hospitalization (Table 1).
Laboratory data obtained prior to the initial IVIG did not
differ between the two groups (Table 2).
With regard to treatment, the initiation date of IVIG
and aspirin administration did not differ, but the total12) Group B (n = 65) p-value
Max) Median (Min–Max)









PE (2) Infliximab (1) Steroids (2)
2 (2–4) 0.020**
Table 2 Baseline laboratory tests (prior to treatment)
Variables Group A Group B p-value
Median (Min–Max)
WBC (/μL) 12190.0 (6760.0–20640.0) 12890.0 (5080.0–30160.0) N.S.
Neutrophil (/μL) 7891.2 (4191.2–13130.1) 8659.0 (3518.1–26771.2) N.S.
Hematocrit (%) 33.2 (27.4–37.9) 31.7 (25.1–41.1) N.S.
Platelet (×104/μL) 36.3 (2.37–54.7) 38.6 (20.0–86.9) N.S.
Total Bilirubin (mg/dL) 0.7 (0.3–2.4) 0.6 (0.1–4.6) N.S.
AST (IU/L) 93.0 (22.0–290.0) 42.0 (20.0–648.0) N.S.
ALT (IU/L) 184.5 (14.0–364.0) 42.0 (7.0–606.0) N.S.
Sodium (mEq/L) 135.0 (130.0–139.0) 136.0 (130.0–143.0) N.S.
CRP (mg/dL) 8.8 (4.2–15.3) 7.4 (0.8–18.7) N.S.
Albumin (g/dL) 3.5 (2.8–3.8) 3.5 (2.5–4.3) N.S.
D-dimer (μg/mL) 1.9 (1.0–8.9) 1.3 (0.5–10.3) N.S.
Fibrinogen (mg/dL) 379.0 (550.0–875.0) 607.0 (392.0–901.0) N.S.
ESR (60 min) (mm) 100.5 (53.0–130.0) 99.0 (38.0–140.0) N.S.
Note: Mann-Whitney test, N.S.: not significant.
WBC White blood cell, AST Aspartate aminotransferase, ALT Alanine aminotransferase.
CRP C-reactive protein, ESR Erythrocyte sedimentation rate.
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(p = 0.02). A second course of IVIG was administered to
six of the 12 patients (50%) in group A and to 14 of the
65 patients (22%) in group B. One patient in group A re-
ceived a third dose of IVIG, and in group B two patients
received prednisolone, one patient received infliximab,
and two patients received plasma exchange (Table 1).
Seven of 77 patients (9.1%) developed CAA, four of
the 12 patients (33.3%) in group A and three of the 65
patients (4.6%) in group B (Table 3). Among them, three
patients in group A and one patient in group B devel-
oped CAA after their fever subsided. Of particular inter-
est, one patient in group A suffered from progressively
worsening CAA that resulted in a giant coronary aneur-
ism during afebrile convalescence. Two other patients in
group A had elevated CRP levels one month after the
onset of illness. The adjusted odds ratio for CAA inTable 3 Details of patients who developed coronary artery ab






At defervescence At 1 mo
Day RCA LCA RCA
Group A 1 F 4 conjunctivitis lip
erythema
13 1.7 2.0 3.3
2 F 11 lip erythema 10 2.2 1.8 4.5
3 M 47 conjunctivitis 12 2.6 2.5 4.5
4 M 17 lip erythema 12 3.4 7.5 2.8
Group B 5 M 28 None 18 3.1 3.5 2.6
6 M 37 None 9 2.0 2.8 2.5
7 M 4 None 7 2.1 1.9 4.2
Note: CA Coronary artery, LCA Left coronary artery, RCA Right coronary artery, n.d. Ngroup A patients was 10.3 (95% CI 1.9–54.8, p = 0.001)
compared with patients in group B. With regard to the
long term prognosis of CAA in these patients, at one year
after the onset of KD, two patients in group A still had cor-
onary artery dilatation or aneurysm, and three patients in
group A and two patients in group B had been treated with
anticoagulant therapy.
Discussion
Although the efficacy of IVIG in reducing the incidence
of CAA in KD is well documented, 10–20% of patients
do not respond to the initial administration of IVIG.
Many researchers have attempted to identify risk factors
associated with IVIG resistance based on the persistence
of fever, but not on the other signs and symptoms of KD
[12-14]. However, in practice, we have managed patients
who had lip erythema and/or bulbar conjunctivitis longnormalities




therapy at 1 year
after onset
nth after onset At 1 year after onset
LCA RCA LCA
2.1 2.1 1.9 4.0 Yes
4.5 3.0 2.3 2.9 Yes
8.7 2.5 2.5 ≤0.2 Yes
7.8 2.7 4.5 n.d. No
3.4 2.0 2.2 n.d Yes
3.3 2.6 2.9 ≤0.2 No
4.4 2.2 2.2 n.d. Yes
ot done.
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of 77 patients 57 attained defervescence after their first
IVIG, but of these 57 patients 12 (15.6%) had one or two
of the non-fever symptoms of KD at their follow up visit
a month after the onset of illness. Importantly, four of
these 12 patients (33.3%) developed CAA. Of these four
patients, three developed CAA after defervescence had
been attained. Of note, CRP levels in two of these pa-
tients remained elevated at one month after the onset of
illness, whereas all the patients in group A who did not
develop CAA had CRP values less than 0.2 mg/dl (data
not shown). Although one patient in group B also devel-
oped CAA, our findings suggest that defervescence
alone is not sufficient to define the responsiveness of KD
patients to IVIG. If patients show persistent non-fever
symptoms after defervescence, cardiac ultrasound and
inflammatory laboratory markers should be closely mon-
itored. The adjusted odds ratio of developing CAA in
this group of patients was as high as 10.3 compared with
the patients who attained defervescence with no persist-
ent non-fever symptoms after initial IVIG (p = 0.001).
At present, we do not understand the pathogenesis of
the prolonged non-fever symptoms. The initial day of
IVIG treatment and the baseline laboratory data were
not significantly different between the two groups. The
patients in group A received a higher total dosage of
IVIG than patients in group B, but the additional treat-
ment was primarily directed against fever. The duration
of fever was not different between the two groups. While
the resolution of fever after IVIG may indicate improve-
ment in systemic inflammation, the persistence of non-
fever symptoms may suggest the presence of localized
vascular inflammation, including in the coronary arter-
ies, even after patients have achieved defervescence. The
elevated CRP observed in some patients at one month
after the onset of illness supports this hypothesis. There-
fore, we believe that the definition of IVIG resistance
should be reconsidered to include the persistence of
non-fever symptoms as well as fever.
Our study has several limitations. First, we could not
observe the patients regularly after their hospital dis-
charge and the presence or absence of non-fever symp-
toms was primarily determined by one of the attending
physicians at an outpatient clinic. However, persistence
of non-fever symptoms in patients who developed CAA
was evaluated by at least two physicians. Second, we did
not treat patients who did not respond to initial IVIG
using a standardized protocol. As discussed in the Results
section, the patients who did not achieve defervescence
after the second IVIG were given additional treatment.
The different additional modalities may have affected the
incidence of CAA in these patients. However, more re-
fractory patients might have been included in group B,
because five patients were treated with prednisolone(n = 2), infliximab (n = 1) and plasma exchange (n = 1).
Third, we examined only a small number of patients ad-
mitted to one institution in this study. Therefore, this small
cohort study still has limitation to conclude that persistent
non-fever symptoms should be included as one of the defi-
nitions of IVIG resistance, and such patients may be at risk
of developing CAA, even after defervescence.
Conclusion
Our study demonstrated that among patients who attained
defervescence after their first IVIG, a certain percentage
had one or two of the non-fever symptoms of KD a month
after the onset of illness. The persistence of these non-
fever symptoms may be an important risk factor for CAA
and may indicate the need for further treatment. Patients
with persistent non-fever symptoms after defervescence re-
quire close and continuous follow-up of cardiac ultrasound
and inflammatory laboratory markers. However, prospect-
ive cohort study with larger number of patients could be
necessary to confirm our result.
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